200 related articles for article (PubMed ID: 37582104)
21. LncRNA WEE2-AS1 is a diagnostic biomarker that predicts poor prognoses in patients with glioma.
Zhu X; Chen D; Sun Y; Yang S; Wang W; Liu B; Gao P; Li X; Wu L; Ma S; Lin W; Ma J; Yan D
BMC Cancer; 2023 Feb; 23(1):120. PubMed ID: 36747161
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of lncRNA FAM83H-AS1 in ovarian cancer.
Gong YB; Zou YF
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4656-4662. PubMed ID: 31210291
[TBL] [Abstract][Full Text] [Related]
23. METTL3-mediated m6A modification of lnc RNA RHPN1-AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K/AKT pathway.
Cui S
J Clin Lab Anal; 2022 Dec; 36(12):e24761. PubMed ID: 36336887
[TBL] [Abstract][Full Text] [Related]
24. TCP1 regulates PI3K/AKT/mTOR signaling pathway to promote proliferation of ovarian cancer cells.
Weng H; Feng X; Lan Y; Zheng Z
J Ovarian Res; 2021 Jun; 14(1):82. PubMed ID: 34162426
[TBL] [Abstract][Full Text] [Related]
25. High LYRM4-AS1 predicts poor prognosis in patients with glioma and correlates with immune infiltration.
Wang HY; Xie Y; Du H; Luo B; Li Z
PeerJ; 2023; 11():e16104. PubMed ID: 37810780
[TBL] [Abstract][Full Text] [Related]
26. Identification of immune infiltration-related LncRNA FAM83C-AS1 for predicting prognosis and immunotherapy response in colon cancer.
Li G; Feng H; Chen Q; Xue C; Li M; Liu X; Ma S
Transpl Immunol; 2021 Dec; 69():101481. PubMed ID: 34624486
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of lncRNA ZEB1-AS1 Represses Cell Proliferation, Migration, and Invasion Through Mediating PI3K/AKT/mTOR Signaling by miR-342-3p/CUL4B Axis in Prostate Cancer.
Ma T; Chen H; Wang P; Yang N; Bao J
Cancer Biother Radiopharm; 2020 Nov; 35(9):661-672. PubMed ID: 32275162
[No Abstract] [Full Text] [Related]
28. Long non-coding RNA FAM83H-AS1 acts as a potential oncogenic driver in human ovarian cancer.
Yuan X; Huang Y; Guo M; Hu X; Li P
J Ovarian Res; 2021 Jan; 14(1):6. PubMed ID: 33413565
[TBL] [Abstract][Full Text] [Related]
29. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
[TBL] [Abstract][Full Text] [Related]
30. LncRNA HAND2-AS1 exerts anti-oncogenic effects on ovarian cancer via restoration of BCL2L11 as a sponge of microRNA-340-5p.
Chen J; Lin Y; Jia Y; Xu T; Wu F; Jin Y
J Cell Physiol; 2019 Dec; 234(12):23421-23436. PubMed ID: 31222748
[TBL] [Abstract][Full Text] [Related]
31. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
[TBL] [Abstract][Full Text] [Related]
32. Exosomal lncRNA FOXD3-AS1 upregulates ELAVL1 expression and activates PI3K/Akt pathway to enhance lung cancer cell proliferation, invasion, and 5-fluorouracil resistance.
Mao G; Mu Z; Wu DA
Acta Biochim Biophys Sin (Shanghai); 2021 Nov; 53(11):1484-1494. PubMed ID: 34605863
[TBL] [Abstract][Full Text] [Related]
33. YBX1/lncRNA SBF2-AS1 interaction regulates proliferation and tamoxifen sensitivity via PI3K/AKT/MTOR signaling in breast cancer cells.
Hussain SA; Venkatesh T
Mol Biol Rep; 2023 Apr; 50(4):3413-3428. PubMed ID: 36754932
[TBL] [Abstract][Full Text] [Related]
34. STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301-3p/STAT3 axis and PI3K/AKT signalling pathway.
Wen J; Wang H; Dong T; Gan P; Fang H; Wu S; Li J; Zhang Y; Du R; Zhu Q
Cell Prolif; 2019 Mar; 52(2):e12569. PubMed ID: 30657221
[TBL] [Abstract][Full Text] [Related]
35. High expression of PXDN is associated with poor prognosis and promotes proliferation, invasion as well as migration in ovarian cancer.
Zheng YZ; Liang L
Ann Diagn Pathol; 2018 Jun; 34():161-165. PubMed ID: 29661721
[TBL] [Abstract][Full Text] [Related]
36. The HOXD9-mediated PAXIP1-AS1 regulates gastric cancer progression through PABPC1/PAK1 modulation.
Li J; Pei M; Xiao W; Liu X; Hong L; Yu Z; Peng Y; Zhang J; Yang P; Lin J; Wu X; Lin Z; Tang W; Zhi F; Li G; Xiang L; Li A; Liu S; Chen Y; Wang J
Cell Death Dis; 2023 May; 14(5):341. PubMed ID: 37225681
[TBL] [Abstract][Full Text] [Related]
37. Downregulated Long Non-Coding RNA MSC-AS1 Inhibits Osteosarcoma Progression and Increases Sensitivity to Cisplatin by Binding to MicroRNA-142.
Zhang L; Zhao G; Ji S; Yuan Q; Zhou H
Med Sci Monit; 2020 Mar; 26():e921594. PubMed ID: 32155139
[TBL] [Abstract][Full Text] [Related]
38. LncRNA PAXIP1-AS1 fosters the pathogenesis of pulmonary arterial hypertension via ETS1/WIPF1/RhoA axis.
Song R; Lei S; Yang S; Wu SJ
J Cell Mol Med; 2021 Aug; 25(15):7321-7334. PubMed ID: 34245091
[TBL] [Abstract][Full Text] [Related]
39. Bioinformatic Analysis and Experimental Validation of HMGA2-AS1 as a Prognostic Biomarker Associated with Immune Infiltration in Gastric Cancer.
Lyu G
Recent Pat Anticancer Drug Discov; 2024 Apr; ():. PubMed ID: 38566377
[TBL] [Abstract][Full Text] [Related]
40. A long noncoding RNA AB073614 promotes tumorigenesis and predicts poor prognosis in ovarian cancer.
Cheng Z; Guo J; Chen L; Luo N; Yang W; Qu X
Oncotarget; 2015 Sep; 6(28):25381-9. PubMed ID: 26299803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
